Northern Tablelands MP Adam Marshall welcomed the state government’s Memorandum of Understanding (MOU), signed with GW Pharmaceuticals, that will progress a major new research program for cannabis-based medicines treating children with severe, drug resistant epilepsy.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
Mr Marshall said many children were suffering across the state and that the announcement would provide hope for those families.
“I’m proud that the government is showing incredible progress on this issue,” he said.
“NSW is the first state in Australia to provide legal and safe access to cannabis-based medicines for children suffering from drug resistant epilepsy.”
Mr Marshall said the MOU would facilitate a world first, phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin (CBDV); a compassionate access scheme for EpidiolexÒ, GW’s product containing cannabidiol (CBD) which is currently in late stage trials in paediatric epilepsy in the United States; provision for NSW to host additional Phase 3 clinical trials of EpidiolexÒ in children with treatment-resistant epilepsy; and a phase 4 clinical trial of EpidiolexÒ, based on phase 3 studies. The MOU, between the NSW government and GW Pharm-aceuicals, comes as part of the NSW government’s $21 million commitment to support clinical trials and establish the NSW Centre for Medicinal Cannabis Research and Innovation.
More information about medicinal cannabis in NSW is available at www.health.nsw.gov.au
/cannabis or the Cannabis Trials Help Line on 1800 217 257.
